Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?

KOSOVA B., KOSOVA B., AYGÜNEŞ JAFARI D. D., KOSOVA B., KOSOVA B., KOSOVA B.

TURK PSIKIYATRI DERGISI, cilt.28, sa.2, ss.89-94, 2017 (SSCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5080/u14883
  • Dergi Adı: TURK PSIKIYATRI DERGISI
  • Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.89-94
  • Hacettepe Üniversitesi Adresli: Hayır

Özet

Objective: Methylphenidate is the first-choice medication for the Pervasive Developmental Disorders (PDDs), and comorbid Attention Deficit Hyperactivity Disorder (ADHD). But this approach generally results with poor outcomes, and increased adverse effects. It is aimed to investigate the comparison of cases who diagnosed with PDDs and Mild Mental Retardation (MR) and cases with pure ADHD in terms of the clinical response to MPH. Also we aimed to investigate the relations between CES-1 polymorphism gene and the clinical response to MPH.